November 18th, 2013
The Best Way to Spend a Morning at AHA?
Seth Shay Martin, MD
This cardiology Fellow finds out exactly what will keep him coming back to the AHA.
November 18th, 2013
No Evidence That Statins Impact Cognitive Function
Larry Husten, PHD
In 2012 the FDA revised the label of statins to include a warning about reports that the drugs had been linked to memory loss or confusion. The FDA action appeared to be based largely on case reports. Despite concerns about this topic that have appeared sporadically in recent years, no high-quality review of the topic has appeared until now. […]
November 18th, 2013
AHA.13 Headquarters
wpengine
CardioExchange is dedicated to bringing you the latest from AHA.13. Check out our coverage of the conference ─ and some of the great debates these posts have sparked ─ then tell us what you think! News: No Value for Renal-Artery Stenting in CORAL Controversy Erupts Over Accuracy of Cardiovascular Risk Calculator for Guidelines Replacement Versus Repair […]
November 18th, 2013
Selections from Richard Lehman’s Literature Review: November 18th
Richard Lehman, BM, BCh, MRCGP
This week’s topics include the VA-NEPHRON-D and IABP-SHOCK II trials, a study of the sex differences in ACS symptoms among young patients, and more.
November 18th, 2013
No Value for Renal-Artery Stenting in CORAL
Larry Husten, PHD
Previous small studies have failed to find any benefit associated with renal-artery stenting, but the trials have been small and were not powered for clinical outcomes. Now, the CORAL (Cardiovascular Outcomes in Renal Atherosclerotic Lesions) trial, presented at the American Heart Association meeting and published simultaneously in the New England Journal of Medicine, offers strong and persuasive evidence that […]
November 18th, 2013
What’s the Moral from CORAL?
Richard A. Lange, MD, MBA and L. David Hillis, MD
Rick Lange and David Hills ask, “Should we stop screening for renal artery stenosis?”
November 18th, 2013
Controversy Erupts Over Accuracy of Cardiovascular Risk Calculator for Guidelines
Larry Husten, PHD
In the face of a highly critical story in the New York Times by Gina Kolata about the new cardiovascular guidelines, authors of the guidelines and leaders of the American Heart Association (AHA) and the American College of Cardiology (ACC) defended the value and integrity of the guidelines. The Times story claims that the cardiovascular risk calculator used to assess individual risk in the new guidelines is […]
November 18th, 2013
Cutting-Edge Lifestyle and Behavioral Interventions — Promises and Challenges at AHA.13
Siqin Ye, MD
Do the studies discussed at the second Late-Breaking Clinical Trial Session show us the way to an exciting new era in prevention?
November 18th, 2013
Replacement Versus Repair for Mitral Valve Regurgitation
Larry Husten, PHD
Surgery is thought to be life-saving for people who have ischemic mitral regurgitation, but it is unknown whether surgical repair or surgical replacement of the mitral valve is the better procedure. Repair is thought to result in fewer preoperative deaths and replacement is thought to have better long-term outcomes with a reduced incidence of recurrent […]
November 17th, 2013
The Gaps in the (Guide)Lines?
Siqin Ye, MD
A blogger at the AHA.13 wonders whether we need better algorithms for assessing CV risk in an increasingly diverse U.S. or a better understanding of how to engage our patients under conditions of uncertainty to make the best patient-centered decisions.